(19)
(11) EP 2 272 952 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.08.2012 Bulletin 2012/33

(45) Mention of the grant of the patent:
09.05.2012 Bulletin 2012/19

(21) Application number: 10172676.8

(22) Date of filing: 31.03.2003
(51) International Patent Classification (IPC): 
C12N 9/12(2006.01)
C12N 15/62(2006.01)
 C12N 15/54(2006.01)

(54)

Thermostable or thermoactive DNA polymerase with attenuated 3'-5' exonuclease activity

Thermostabiler oder thermoactiver DNA-polymerase mit abgeschwächter 3'-5' Exonukleaseaktivität

ADN polymérase thermostable ou thermoactif ayant une activité 3' - 5' exonucléase atténuée

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 02.04.2002 US 369815 P

(43) Date of publication of application:
12.01.2011 Bulletin 2011/02

(62) Application number of the earlier application in accordance with Art. 76 EPC:
03006888.6 / 1350841

(73) Proprietors:
  • Roche Diagnostics GmbH
    68305 Mannheim (DE)
    Designated Contracting States:
    DE 
  • F. Hoffmann-La Roche AG
    4070 Basel (CH)
    Designated Contracting States:
    AT BE BG CH CY CZ DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR 

(72) Inventors:
  • Schönbrunner, Nancy J.
    Moraga, CA 94556 (US)
  • Myers, Thomas W.
    Los Altos, CA 94204 (US)
  • Gelfand, David H.
    Oakland, CA 94611 (US)


(56) References cited: : 
US-A- 5 420 029
 US-B1- 6 228 628
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).